Is This Drug Taking on Water?

The Food and Drug Administration appears to like Cornerstone Therapeutics' (Nasdaq: CRTX  ) lixivaptan -- just not for every indication that Cornerstone wants to market the drug for.

The agency released its view of the drug ahead of Thursday's advisory committee meeting. The reviewer thinks lixivaptan should be approved for people with low salt due to a condition called syndrome of inappropriate antidiuretic hormone secretion, which causes the body to have excess water.

The reviewer wasn't as hot on the drug being used in patients with low salt associated with congestive heart failure. More patients taking lixivaptan died in the clinical trial for heart failure patients than those in the control group, although it wasn't clear if the drug was the actual cause or if it just happened randomly.

That could leave the door open for Cornerstone to convince the panel of outside experts that lixivaptan should be approved for heart failure patients as well. The company likely needs a big win with a vast majority of the committee members recommending approval of the drug in the second indication. A simple majority isn't likely to be enough to change the FDA's mind.

Lixivaptan has had many owners over the years. It was first developed by Wyeth, now part of Pfizer (NYSE: PFE  ) , which licensed it to Cardiokine. That biotech brought in Biogen Idec (Nasdaq: BIIB  ) , but it later handed back the rights to the drug. Cornerstone obtained the drug by purchasing Cardiokine.

Normally when a drug gets shuffled around, it's a bad sign. Biogen passed off Zevalin to Cell Therapeutics (Nasdaq: CTIC  ) , which was then licensed to Spectrum Pharmaceuticals (Nasdaq: SPPI  ) ; the drug brought in just $28 million last year.

But for lixivaptan, it might not be that bad of a sign. Cornerstone bought Cardiokine, so it's not like the company was trying to pass off a flop. And Biogen lost interest when it left the cardiovascular space completely; the decision wasn't lixivaptan-specific.

Before worrying about its commercial prospects, Cornerstone has to convince the advisory committee to recommend approving the drug for one or more indications, and then the FDA has to approve the drug, which should occur on or around Oct. 29.

Not too long after that, we'll have another big binary event: the presidential election. Check out the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies that can benefit from each candidate's platform. Get your free copy by clicking here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 13, 2012, at 11:41 AM, Emperor2 wrote:

    I didn't know that Zevalin's $28 million was a "bad" sign. I wish my company had a $28 million product.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2014754, ~/Articles/ArticleHandler.aspx, 10/22/2014 8:26:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement